Biotechnology News and Research

RSS

Helicos Genetic Analysis System to be installed at the Leiden Genome Technology Center

Helicos BioSciences Corporation, today announced the sale of a Helicos® Genetic Analysis System to a collaborative Dutch research group led by the Leiden University Medical Center (LUMC), further including the medical centers of Amsterdam (AMC) Groningen (UMCG) and Rotterdam (Erasmus MC) and funded by a grant from NWO, the Netherlands Organization of Scientific Research.

17 Nov 2009

Bavarian Nordic awarded a new contract for developing a freeze-dried version of its IMVAMUNE smallpox vaccine

Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.

17 Nov 2009

YM BioSciences presents preclinical results of its small molecule VDA at the AACR-NCI-EORTC conference

YM BioSciences Inc., a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, announced that preclinical results for CYT997 were presented today in a poster by Cytopia Limited at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference in Boston, Massachusetts.

17 Nov 2009

Second-quarter fiscal 2010 results announced by China-Biotics

China-Biotics, Inc., a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced its financial results for the second quarter of its 2010 fiscal year, ended September 30, 2009.

17 Nov 2009

Perceptive Informatics announces the expansion of its medical imaging capabilities for cardiology clinical trials

Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation, today announced that it has expanded its leading medical imaging capabilities with advanced nuclear imaging functionality for cardiology clinical trials.

From Parexel 17 Nov 2009

Molecular makeup of current H1N1 flu strain strikingly different from previous H1N1 strains

As the number of deaths related to the pandemic H1N1 virus, commonly known as "swine flu," continues to rise, researchers have been scrambling to decipher its inner workings and explain why the incidence is lower than expected in older adults.

17 Nov 2009

DNA banking: A step toward preserving history and improving the health of future generations

This Thanksgiving Day marks the sixth annual National Family History Day, a U.S. Department of Health and Human Services initiative to encourage families to discuss their health history. Holiday gatherings are excellent opportunities for discussing and documenting family disease backgrounds which can save the lives of loved ones through early detection and preventive measures.

17 Nov 2009

Genzyme receives FDA complete response letter for its Lumizyme marketing application

Genzyme Corporation announced today that it has received a complete response letter from the FDA regarding its application to market Lumizyme™ (alglucosidase alfa) for the treatment of Pompe disease. In its letter, the agency stated that satisfactory resolution of deficiencies related to the Allston Landing manufacturing plant are required before the Lumizyme application can be approved.

17 Nov 2009

Genentech submits sBLAs to the FDA for Avastin

Genentech, Inc., a wholly-owned member of the Roche Group, today announced that the company submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Avastin® (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic) HER2-negative breast cancer (first-line treatment). One sBLA is based on the Phase III study AVADO that investigated Avastin in combination with docetaxel chemotherapy.

17 Nov 2009

ThromboGenics and BioInvent International present phase I results of novel anti-cancer monoclonal antibody

ThromboGenics NV and BioInvent International AB today announced positive results from a Phase I trial of their novel anti-cancer monoclonal antibody TB-403 in patients with advanced solid tumours. The results were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, U.S. TB-403 was well tolerated with no reported dose limiting toxicity. These positive data support progression of TB-403 and further development.

17 Nov 2009

PPD, Janssen Pharmaceutica to develop therapeutic compounds for IBS and bacterial infections

PPD, Inc. today announced it has entered an agreement with Janssen Pharmaceutica N.V. to develop and commercialize two Phase II-ready therapeutic compounds, one to treat diarrhea-predominant irritable bowel syndrome (IBS-d) and the other to treat complicated skin and skin structure and respiratory infections.

17 Nov 2009

Scientists find major genetic differences between the pandemic H1N1 strain and seasonal strains

17 Nov 2009

Targeted Genetics announces third quarter 2009 results; reports net income of $0.03 per common share

Targeted Genetics Corporation today announced its financial results for the third quarter ended September 30, 2009.

17 Nov 2009

Kane Biotech to raise $500,000 through private placement

Kane Biotech Inc., a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, today announces a non-brokered private placement offering for gross proceeds of up to $500,000 consisting of up to 3,846,154 units ("Units") at a price of $0.13 per Unit.

16 Nov 2009

Dyadic International reports financial results for the third quarter of 2009

Dyadic International, Inc. today announced financial results for the third quarter ended September 30, 2009. The financial information contained in this press release should be read in conjunction with the financial statements and footnotes for the three and nine month periods ended September 30, 2009 as well as the financial statements, footnotes and independent auditors’ report for the year ended December 31, 2008 which have been posted on the Pink Sheets website at www.pinksheets.com and on Dyadic’s website at www.dyadic.com.

16 Nov 2009

ECR Pharmaceuticals to commercialize and manufacture ZolpiMist in the U.S. and Canada

NovaDel Pharma Inc. today announced its entry into an exclusive license and distribution agreement with ECR Pharmaceuticals Company, Inc., a wholly owned subsidiary of Hi-Tech Pharmacal Co., Inc. to commercialize and manufacture ZolpiMist™ in the United States and Canada. ZolpiMist™ is our oral spray formulation of zolpidem tartrate approved by the FDA in December of 2008.

16 Nov 2009

Semafore Pharmaceuticals to present SF1126 Phase I data at the 51st ASH meeting

Researchers are scheduled to present Phase I data relating to Semafore Pharmaceuticals’ lead product candidate, SF1126, as a treatment for patients with relapsed and refractory myeloma during the 51st American Society of Hematology (ASH) Annual Meeting, December 5 - 8, 2009, at the Ernst N. Morial Convention Center in New Orleans, LA.

16 Nov 2009

Seattle Genetics commences phase I clinical trial of SGN-75 ADC for metastatic renal cell carcinoma

Seattle Genetics, Inc. today announced that it has initiated a phase I clinical trial of SGN-75 for metastatic renal cell carcinoma and relapsed and refractory non-Hodgkin lymphoma. SGN-75 is an antibody-drug conjugate (ADC) targeting CD70 that utilizes the company’s proprietary technology.

16 Nov 2009

Drug makers hike prices, lobby hard as reform efforts progress

Drug makers are bracing for reform by raising their prices - by 9 percent in the last year, perhaps the fastest rate since 1992, The New York Times reports. This happened "even as drug makers promise to support Washington's health care overhaul by shaving $8 billion a year off the nation's drug costs after the legislation takes effect." The increases "will add more than $10 billion to the nation's drug bill, which is on track to exceed $300 billion this year."

16 Nov 2009

Genetic test for familial Dilated Cardiomyopathy launched by PGxHealth

PGxHealth, a division of Clinical Data, Inc., today announced the launch of its genetic test for familial Dilated Cardiomyopathy, an inherited heart disease which is the leading cause of heart transplants and a possible cause of sudden cardiac death.

16 Nov 2009

Biotechnology News and Research

Helicos Genetic Analysis System to be installed at the Leiden Genome Technology Center

Bavarian Nordic awarded a new contract for developing a freeze-dried version of its IMVAMUNE smallpox vaccine

YM BioSciences presents preclinical results of its small molecule VDA at the AACR-NCI-EORTC conference

Second-quarter fiscal 2010 results announced by China-Biotics

Perceptive Informatics announces the expansion of its medical imaging capabilities for cardiology clinical trials

Molecular makeup of current H1N1 flu strain strikingly different from previous H1N1 strains

DNA banking: A step toward preserving history and improving the health of future generations

Genzyme receives FDA complete response letter for its Lumizyme marketing application

Genentech submits sBLAs to the FDA for Avastin

ThromboGenics and BioInvent International present phase I results of novel anti-cancer monoclonal antibody

PPD, Janssen Pharmaceutica to develop therapeutic compounds for IBS and bacterial infections

Scientists find major genetic differences between the pandemic H1N1 strain and seasonal strains

Targeted Genetics announces third quarter 2009 results; reports net income of $0.03 per common share

Kane Biotech to raise $500,000 through private placement

Dyadic International reports financial results for the third quarter of 2009

ECR Pharmaceuticals to commercialize and manufacture ZolpiMist in the U.S. and Canada

Semafore Pharmaceuticals to present SF1126 Phase I data at the 51st ASH meeting

Seattle Genetics commences phase I clinical trial of SGN-75 ADC for metastatic renal cell carcinoma

Drug makers hike prices, lobby hard as reform efforts progress

Genetic test for familial Dilated Cardiomyopathy launched by PGxHealth

Biotechnology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News